



From left: Carmen Herrera and Pål Falnes. Photo: Jarli&Jordan/University of Oslo

Blood-Based test for monitoring lung cancer

Our team is developing a non-invasive test to monitor lung cancer using a novel biomarker with high sensitivity and specificity, based on a newly identified human protein methyltransferase.

Application

This novel, blood-based test aims to monitor lung cancer and could potentially be integrated into standard patient monitoring and annual checkups.

Market assessment

The global lung-cancer monitoring market is expected to be worth USD 2-3Bn by 2030, growing at a CAGR of 13.3 % during the forecast period.

Competitive advantages

A highly sensitive and novel biomarker detectable in plasma for lung cancer monitoring.

IP status

Patent application in preparation.

Needs

Technology development and validation of the plasma biomarker.

Project leader

Carmen Herrera
University of Oslo
M.d.c.h.gonzalez-molina@ibv.uio.no

Project coordinator

Audun Tornes,
COO at RAB Diagnostics

The team

- Pål Falnes, UiO
- Katja Mjøs, UiO Growth House

SPARK
— NORWAY —



UNIVERSITY
OF OSLO